ArticleTransboundary and emerging diseases2026
Vaccine-Associated Recombination and Virulence Heterogeneity of GI-19 (QX Type) Infectious Bronchitis Virus in Eastern and Southern China, 2024-2025.
Article in Transboundary and emerging diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Vaccination-driven evolution of infectious bronchitis virus in Korea: implication for the control of other coronavirus infections.Frontiers in veterinary science · 2026Review
- Vaccine-Associated Recombination and Virulence Heterogeneity of GI-19 (QX Type) Infectious Bronchitis Virus in Eastern and Southern China, 2024-2025.Transboundary and emerging diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infectious bronchitis (IB) virus (IBV) remains a major pathogen threatening the poultry industry. Its rapid mutation and recombination continuously generate variants that disseminate worldwide. Between May 2024 and February 2025, 49 field strains were isolated from chickens vaccinated with live-attenuated IBV vaccines (H120, 4/91, or QXL87) in four Chinese provinces (Jiangsu, Anhui, Shandong, and Guangdong). Based on full-length S1 gene sequencing, all isolates were classified into genotype GI, including lineages GI-13 and GI-19. Phylogenetic analysis revealed that GI-19 (QX-type) comprised as much as 83.67%, with the nucleotide homology of the S1 gene to QXL87 varying from 93.4% to 99.8%. Recombination analysis indicated that the S1 genes of three isolates incorporate QXL87 and 4/91 genetic material, possibly arising from recombination between the QX-type and 4/91 vaccine strains. Virulence assessment in 1-day-old specific-pathogen-free (SPF) chickens demonstrated that four phylogenetically distant QX-type strains and one recombinant strain (with QXL87 as the major parent) induced varying degrees of tissue damage and mortality. Cross-neutralization assays demonstrated reduced antigenic relatedness between the circulating isolates and QXL87 vaccine strain. Structural mapping analysis further indicated that three amino acid mutations within the N-terminal domain (NTD) and two amino acid mutations in the C-terminal domain (CTD) of the S1 subunit alter its overall conformation, potentially leading to antigenic variation and facilitating immune evasion. Overall, these findings offer timely insights into the epidemiology and virulence heterogeneity of QX-IBV, providing valuable references for optimizing vaccine selection and development, as well as for preventing and controlling the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.